The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Conditional transgenic technologies
Open accessAbstract
Transgenic technology has been revolutionised by the development of techniques that allow temporo-spatial control of gene deletion or expression in transgenic animals. The ability to switch gene expression 'on' or 'off' in restricted tissues at specific times allows unprecedented flexibility for exploring gene function in both health and disease. As use of these techniques grows in all areas of biomedical research, an understanding of this topic is essential. In this review we examine the theory, application and limitations of these strategies, with particular reference to endocrine research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943 · cited 1×
“Two modifications have been made to suit transgenic purposes (Gossen & Bujard 1992).”
BackgroundTranscriptional Activation by Tetracyclines in Mammalian Cells
Gossen, M., Freundlieb, S., Bender, G., Müller, G., Hillen, W., & Bujard, H. (1995) · Science · doi:10.1126/science.7792603 · Cited by 2,488 · cited 1×
“Reverse tTA (rtTA) is a mutagenised version which binds tetO in the presence of doxycycline and activates transcription (Gossen et al. 1995) (Fig.”
BackgroundMetzger, D., Clifford, J., Chiba, H., & Chambon, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6991 · Cited by 570 · cited 1×
“Fusion of the ligand-binding domain (LBD) of a mutated oestrogen receptor to Cre results in a hybrid that is active in the presence of tamoxifen, but not endogenous steroids (Metzger et al. 1995).”
BackgroundRohlmann, A., Gotthardt, M., Hammer, R. E., & Herz, J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1240 · Cited by 455 · cited 1×
“Kuhn et al. (1995) have used an interferon-inducible promoter to control Cre expression, and this has been used successfully to delete the low density lipoprotein receptor-related protein in hepatocytes (Rohlmann et al. 1998).”
Method
Cited by
Banaszynski, L. A., Chen, L.-C., Maynard-Smith, L. A., Ooi, A. G. L., & Wandless, T. J. (2006) · Cell · doi:10.1016/j.cell.2006.07.025 · Cited by 902
Embryonic Stem Cells: Prospects for Developmental Biology and Cell Therapy
Wobus, A. M., & Boheler, K. R. (2005) · Physiological Reviews · doi:10.1152/physrev.00054.2003 · Cited by 782
Target-based drug discovery: is something wrong?
Sams-Dodd, F. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03316-1 · Cited by 522
Moullan, N., Mouchiroud, L., Wang, X., Ryu, D., Williams, E. G., Mottis, A., Jovaisaite, V., Frochaux, M. V., Quiros, P. M., Deplancke, B., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.034 · Cited by 470
Metabolic Pitfalls of CNS Cre-Based Technology
Harno, E., Cottrell, E. C., & White, A. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.019 · Cited by 200
Metadata
- Authors
- Ryding, A., Sharp, M., & Mullins, J.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2001-10-01
- Volume
- 171
- Issue
- 1
- Pages
- 1-14
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2134685898
- Cited by
- 160
- References
- 4
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Conditional transgenic technologies. https://app.cochat.ai/papers/10.1677/joe.0.1710001
- The paper
- Ryding, A., Sharp, M., & Mullins, J. (2001). Conditional transgenic technologies. Journal of Endocrinology. https://doi.org/10.1677/joe.0.1710001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
